153 related articles for article (PubMed ID: 17164694)
1. Inhibitory effects of propafenone on the pharmacokinetics of caffeine in humans.
Michaud V; Mouksassi MS; Labbé L; Bélanger PM; Ferron LA; Gilbert M; Grech-Bélanger O; Turgeon J
Ther Drug Monit; 2006 Dec; 28(6):779-83. PubMed ID: 17164694
[TBL] [Abstract][Full Text] [Related]
2. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2.
Kinzig-Schippers M; Fuhr U; Zaigler M; Dammeyer J; Rüsing G; Labedzki A; Bulitta J; Sörgel F
Clin Pharmacol Ther; 1999 Mar; 65(3):262-74. PubMed ID: 10096258
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings.
Labbé L; O'Hara G; Lefebvre M; Lessard E; Gilbert M; Adedoyin A; Champagne J; Hamelin B; Turgeon J
Clin Pharmacol Ther; 2000 Jul; 68(1):44-57. PubMed ID: 10945315
[TBL] [Abstract][Full Text] [Related]
4. Propafenone: a new antiarrhythmic agent.
Chow MS; Lebsack C; Hilleman D
Clin Pharm; 1988 Dec; 7(12):869-77. PubMed ID: 3061720
[TBL] [Abstract][Full Text] [Related]
5. A pharmacometric approach to investigate the impact of methylxanthine abstinence and caffeine consumption on CYP1A2 activity.
Perera V; Gross AS; Forrest A; Landersdorfer CB; Xu H; Ait-Oudhia S; McLachlan AJ
Drug Metab Dispos; 2013 Nov; 41(11):1957-66. PubMed ID: 23996078
[TBL] [Abstract][Full Text] [Related]
6. Effect of CYP2D6*10 genotype on propafenone pharmacodynamics in Chinese patients with ventricular arrhythmia.
Cai WM; Xu J; Chen B; Zhang FM; Huang YZ; Zhang YD
Acta Pharmacol Sin; 2002 Nov; 23(11):1040-4. PubMed ID: 12421483
[TBL] [Abstract][Full Text] [Related]
7. Comparative pharmacokinetics and clinical pharmacology of propafenone enantiomers after oral administration to man.
Brode E; Müller-Peltzer H; Hollmann M
Methods Find Exp Clin Pharmacol; 1988 Nov; 10(11):717-27. PubMed ID: 3221745
[TBL] [Abstract][Full Text] [Related]
8. Effects of major tanshinones isolated from Danshen (Salvia miltiorrhiza) on rat CYP1A2 expression and metabolism of model CYP1A2 probe substrates.
Wang X; Lee WY; Or PM; Yeung JH
Phytomedicine; 2009 Aug; 16(8):712-25. PubMed ID: 19403289
[TBL] [Abstract][Full Text] [Related]
9. Investigations on the pharmacokinetics of propafenone in man.
Hollmann M; Brode E; Hotz D; Kaumeier S; Kehrhahn OH
Arzneimittelforschung; 1983; 33(5):763-70. PubMed ID: 6683556
[TBL] [Abstract][Full Text] [Related]
10. [Effect of propafenone on the pharmacokinetics of digoxin administered orally: a study in healthy volunteers].
Cardaioli P; Compostella L; De Domenico R; Papalia D; Zeppellini R; Libardoni M; Pulido E; Cucchini F
G Ital Cardiol; 1986 Mar; 16(3):237-40. PubMed ID: 3732716
[TBL] [Abstract][Full Text] [Related]
11. Stereoselective disposition of the antiarrhythmic agent mexiletine during the concomitant administration of caffeine.
Labbé L; Abolfathi Z; Robitaille NM; St-Maurice F; Gilbert M; Turgeon J
Ther Drug Monit; 1999 Apr; 21(2):191-9. PubMed ID: 10217339
[TBL] [Abstract][Full Text] [Related]
12. Effect of sodium tanshinone II A sulfonate on the activity of CYP1A2 in healthy volunteers.
Chen Y; Tu JH; He YJ; Zhang W; Wang G; Tan ZR; Zhou G; Fan L; Zhou HH
Xenobiotica; 2009 Jul; 39(7):508-13. PubMed ID: 19534587
[TBL] [Abstract][Full Text] [Related]
13. The effects of puerarin on CYP2D6 and CYP1A2 activities in vivo.
Zheng J; Chen B; Jiang B; Zeng L; Tang ZR; Fan L; Zhou HH
Arch Pharm Res; 2010 Feb; 33(2):243-6. PubMed ID: 20195825
[TBL] [Abstract][Full Text] [Related]
14. Caffeine pharmacokinetics during hyperbaric hyperoxia in humans.
Rump AF; Siekmann U; Dreja M; Kalff G
Aviat Space Environ Med; 1997 Feb; 68(2):142-6. PubMed ID: 9125091
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine.
Zandvliet AS; Huitema AD; de Jonge ME; den Hoed R; Sparidans RW; Hendriks VM; van den Brink W; van Ree JM; Beijnen JH
Basic Clin Pharmacol Toxicol; 2005 Jan; 96(1):71-9. PubMed ID: 15667599
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous modeling of pharmacokinetics and pharmacodynamics of propafenone in healthy subjects.
Cai WM; Zhang YD; Chen B; Cai MH; Luo JP; Ling SS
Acta Pharmacol Sin; 2001 Oct; 22(10):956-60. PubMed ID: 11749782
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors.
Mao ZL; Wheeler JJ; Clohs L; Beatch GN; Keirns J
J Clin Pharmacol; 2009 Jan; 49(1):17-29. PubMed ID: 18927241
[TBL] [Abstract][Full Text] [Related]
18. Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: a pilot study.
Härtter S; Ursing C; Morita S; Tybring G; von Bahr C; Christensen M; Röjdmark S; Bertilsson L
Clin Pharmacol Ther; 2001 Jul; 70(1):10-6. PubMed ID: 11452239
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2.
Kobayashi K; Nakajima M; Chiba K; Yamamoto T; Tani M; Ishizaki T; Kuroiwa Y
Br J Clin Pharmacol; 1998 Apr; 45(4):361-8. PubMed ID: 9578183
[TBL] [Abstract][Full Text] [Related]
20. Concentration dependent stereoselectivity of propafenone N-depropylation metabolism with human hepatic recombinant CYP1A2.
Zhou Q; Yao TW; Yu YN; Zeng S
Pharmazie; 2003 Sep; 58(9):651-3. PubMed ID: 14531463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
